A Phase 3 interventional study of ticagrelor and Acetylsalicylic acid (ASA) in Acute Ischaemic Stroke and Transient Ischaemic Attack, sponsored by AstraZeneca. Completed at 528 sites in 33 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-06-12.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Ischemic Attack, Transient with a site in United States — 10 open to participants now, 14 under way, 1 of them phase 3. Ischemic Attack, Transient · United States.
Among the 88 studies in Ischemic Attack, Transient with a site in United States, this one has the largest enrollment of the 65 interventional ones that give a count, is one of 4 that started in 2014, is one of 12 in phase 3, and was the 48th registered.
329 studies on the registry are indexed under Ischemic Attack, Transient; 71 are open to participants now.
Browse Ischemic Attack, Transient studies →10 of the 88 studies in Ischemic Attack, Transient with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–99
Kessler Foundation · Sites in United States
Ages 18–75
University of Alabama at Birmingham · Sites in United States
Ages 18–89
University of Washington · Sites in United States
Ages 40–65
Louis Stokes VA Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Ischemic Attack, Transient studies recruiting now, 36 (67%) set no upper age limit and 6 (11%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.
This study: 40 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 16 · Phase 4 3
First in 1998; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13,307 is above the median of 217 across 178 interventional studies indexed under Ischemic Attack, Transient.
Median enrollment 202 across the 65 interventional studies, 318 across the 22 observational. Of the 63 that completed or were terminated, 31 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 88 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 4 studies filed under Ischemic Attack, Transient — fewer than ten, so there is no comparison to draw.
3 of the studies in Ischemic Attack, Transient with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07414732Massachusetts General HospitalTesting the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke Survivors | 2027-04-30 |
| NCT07916883Washington University School of MedicinePET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite) | 2027-05-31 |
| NCT02098265University of Wisconsin, MadisonA Closed Loop Neural Activity Triggered Stroke Rehabilitation Device | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 88 studies in Ischemic Attack, Transient with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (ASA)-aspirin (300 mg [three 100 mg tablets] loading dose on Day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction [MI], and death) in patients with acute ischaemic stroke or transient ischaemic attack (TIA).
Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ticagrelor
Drug: Acetylsalicylic acid (ASA)
ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
Number of Participants With Composite of Stroke/MI/Death
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Number of Participants With Ischaemic Stroke
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Net Clinical Outcome
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Number of Participants With Composite of Ischaemic Stroke, MI and CV Death
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Number of Participants With All-Cause Death
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Number of Participants With CV Death
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Number of Participants With MI
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)
Time frame: From randomization up to 97 days
Number of Participants by Severity of Stroke and Overall Disability
Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS. Modified Rankin Score: 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead. Disability defined as mRS \> 1. Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables.
Time frame: From randomization up to 97 days
Number of Participants With Stroke
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)
Time frame: From randomization up to 97 days
Number of Participants With Fatal Stroke
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Number of Participants With Disabling Stroke
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).
Time frame: From randomization up to 97 days
Change in NIHSS
Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale): 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke.
Time frame: From randomization up to 97 days
EQ-5D at Visit 1 (Enrolment)
EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
Time frame: Visit 1 (Enrolment)
EQ-5D at Visit 2 (Day 7+-2d)
EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
Time frame: Visit 2 (Day 7+-2d)
EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit
EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
Time frame: End of treatment visit (Day 90+-7d)
EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit
EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
Time frame: Premature treatment discontinuation visit(<15 days after last dose)
Number of Participants With PLATO Major Bleeding Event
Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). PLATO Major bleeding is defined as a bleed that is any one of: * Fatal * Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages \<10 mm evident only on gradient-echo MRI) * Intrapericardial bleed with cardiac tamponade * Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery * Significantly disabling (eg. intraocular with permanent vision loss) * Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L) * Transfusion of 2 or more units (whole blood or packed red blood cells \[PRBCs\]) for bleeding.
Time frame: From randomization up to 97 days
Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).
Time frame: Time from first dose and up to and including 7 days following the date of last dose of the study
In total, 13307 patients were enrolled from 674 study sites in 33 countries. The first patient was enrolled on 07 January 2014. The last patient visit took place on 02 March 2016.
| Milestone | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Started | 6589 | 6610 |
| Completed | 6543 | 6554 |
| Not completed | 46 | 56 |
| Withdrew: Withdrawal by subject | 46 | 56 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With Composite of Stroke/MI/Death | 442 | 497 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With Ischaemic Stroke | 385 | 441 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Net Clinical Outcome | 457 | 508 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With Composite of Ischaemic Stroke, MI and CV Death | 423 | 475 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With All-Cause Death | 68 | 58 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With CV Death | 41 | 35 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With MI | 25 | 21 |
Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS. Modified Rankin Score: 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead. Disability defined as mRS \> 1. Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables.
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants by Severity of Stroke and Overall Disability | 1107 | 1194 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With Stroke | 390 | 450 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With Fatal Stroke | 18 | 17 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With Disabling Stroke | 277 | 307 |
Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale): 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke.
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| <=-5 | 132 | 127 |
| -4 | 403 | 438 |
| -3 | 779 | 810 |
| -2 | 1088 | 1073 |
| -1 | 1099 | 1131 |
| 0 | 681 | 683 |
| 1 | 67 | 79 |
| 2 | 28 | 31 |
| 3 | 18 | 16 |
| 4 | 13 | 11 |
| 5 | 6 | 6 |
| >5 | 10 | 14 |
| Missing | 474 | 450 |
EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
| Index score | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| EQ-5D at Visit 1 (Enrolment) | 0.70 ± 0.297 | 0.70 ± 0.298 |
EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
| Index score | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| EQ-5D at Visit 2 (Day 7+-2d) | 0.80 ± 0.244 | 0.79 ± 0.262 |
EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
| Index score | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit | 0.85 ± 0.203 | 0.84 ± 0.208 |
EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.
| Index score | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit | 0.72 ± 0.330 | 0.68 ± 0.364 |
Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). PLATO Major bleeding is defined as a bleed that is any one of: * Fatal * Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages \<10 mm evident only on gradient-echo MRI) * Intrapericardial bleed with cardiac tamponade * Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery * Significantly disabling (eg. intraocular with permanent vision loss) * Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L) * Transfusion of 2 or more units (whole blood or packed red blood cells \[PRBCs\]) for bleeding.
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With PLATO Major Bleeding Event | 31 | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).
| Participants | Ticagrelor 90 mg | ASA 100 mg |
|---|---|---|
| Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event | 82 | 37 |
Collected over On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. 97 days if the participant completed treatment according to the study plan.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ASA 100mg | — | 533/6,581 (8.1%) | 85/6,581 (1.3%) |
| Ticagrelor 90mg | — | 532/6,549 (8.1%) | 383/6,549 (5.8%) |
| Event | ASA 100mg | Ticagrelor 90mg |
|---|---|---|
| Transient ischaemic attackNervous system disorders | 68/6581 | 55/6549 |
| Carotid artery stenosisNervous system disorders | 27/6581 | 28/6549 |
| Atrial fibrillationCardiac disorders | 21/6581 | 24/6549 |
| PneumoniaInfections and infestations | 23/6581 | 19/6549 |
| HypertensionVascular disorders | 11/6581 | 12/6549 |
| Angina unstableCardiac disorders | 4/6581 | 11/6549 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6581 | 11/6549 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/6581 | 4/6549 |
| Urinary tract infectionInfections and infestations | 4/6581 | 8/6549 |
| Cardiac failureCardiac disorders | 7/6581 | 7/6549 |
| Event | ASA 100mg | Ticagrelor 90mg |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 85/6581 | 383/6549 |
| Age, Continuous(Years) | Ticagrelor 90 mg | ASA 100 mg | Total |
|---|---|---|---|
| Mean | 65.8 ± 11.23 | 65.9 ± 11.37 | 65.9 ± 11.30 |
| Age, Customized(Participants) | Ticagrelor 90 mg | ASA 100 mg | Total |
|---|---|---|---|
| <65 years | 3021 | 3007 | 6028 |
| Between 65 and 75 years | 2064 | 2112 | 4176 |
| >75 years | 1504 | 1491 | 2995 |
| Sex: Female, Male(Participants) | Ticagrelor 90 mg | ASA 100 mg | Total |
|---|---|---|---|
| Female | 2759 | 2724 | 5483 |
| Male | 3830 | 3886 | 7716 |
| Ethnicity (NIH/OMB)(Participants) | Ticagrelor 90 mg | ASA 100 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 566 | 558 | 1124 |
| Not Hispanic or Latino | 6023 | 6050 | 12073 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor 90 mg | ASA 100 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 69 | 74 | 143 |
| Asian | 1957 | 1949 | 3906 |
| Native Hawaiian or Other Pacific Islander | 4 | 1 | 5 |
| Black or African American | 119 | 120 | 239 |
| White | 4374 | 4410 | 8784 |
| Other | 66 | 56 | 122 |
Showing the first 100 of 528 sites across 33 countries. Choose a country and city above to see the rest.
Ran from Jan 2014 to primary completion in Mar 2016, 25 months.
Results were first posted in Jun 2017, 1 year 3 months after primary completion.
Of 13 phase 3 interventional studies under Ischemic Attack, Transient, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 51. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor